Sensile Medical achieves important milestone for its patch pump

24.03.2014 08:58

Sensile Medical AG has completed the usability study for the semi-disposable patch pump that is developed for scPharmaceuticals LLC’s novel subcutaneous furosemide therapy. The successful completion of this development milestone paves the way for the company’s first regulatory filings in 2015.

In the study health care professionals (HCPs) from seven hospitals in the United States and The Netherlands responded to questions about the subcutaneous application of furosemide (scFurosemide) in the treatment of heart failure and the handling of Sensile Medical’s new patch pump. The HCPs identified a broad range of clinical situations where scFurosemide treatment may improve both, the care process as well as patients’ outcomes.

The opportunity to treat patients with early stages of decompensation outside the emergency room or hospital emerged as the main advantage of this new scFurosemide treatment option over the current intravenous administration.  The study participants expressed a strong interest in the use of the scFurosemide patch pump to better and more cost-effectively manage patients with heart failure.

“Using these devices with scFurosemide patients will be able to initiate effective treatment earlier when symptoms deteriorate.” said Rudolf Sidler, PhD, Product Manager at Sensile Medical. “In many cases this may prevent a visit to the emergency room or need for in-patient stay. “

“We are very pleased with the results of the study. They confirmed that we are on the right track with this unique combination product.” said Pieter Muntendam, MD, President and CEO of scPharmaceuticals. “Sensile’s precise micro pump technology enables a new generation of cost-effective devices previously not possible.”

Sensile Medical and scPharmaceuticals entered into a strategic partnership and supply agreement in the first quarter of 2013. The successful completion of this development milestone paves the way for the company’s first regulatory filings in 2015.

Principal

Partners

Contributors